Clinical Trials Browser

Interventional × Prolactinoma × Endocrine × Clear all

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT03457389 2020-03-18

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Phase NA Unknown

68 enrolled

Endocrine

Pituitary Neoplasms, Recurrence, Prolactinoma

NCT00939523 2020-01-22

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Phase 2 Completed

9 enrolled 11 charts

Endocrine

Pituitary Neoplasms, Prolactinoma

NCT01775332 2015-07-31

Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools

Phase NA Unknown

60 enrolled

Endocrine

Gigantism, Pituitary Neoplasms, Prolactinoma, Growth Hormone-Secreting Pituitary Adenoma, ACTH-Secreting Pituitary Adenoma

NCT01088763 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Phase 1 Terminated

129 enrolled

CNSEndocrineLymphoidOther hematologic neoplasmSarcoma

Familial ependymoma, Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Oligodendroglioma, Pituitary Neoplasms, Recurrence, Spinal Cord Neoplasms, Prolactinoma, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Rhabdoid Tumor, Optic Nerve Glioma, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Clinical Trials

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia